


Summary

| Name | calreticulin-3/CALR3/CRT2 |
|--------------------------|--|
| Purity | Greater than 95% as determined by reducing SDS-PAGE |
| Endotoxin level | <1 EU/µg as determined by LAL test. |
| Construction | Recombinant Human Calreticulin-3 is produced by our E.coli expression |
| Accession # | system and the target gene encoding Thr20-Leu384 is expressed. Q96L12 |
| Host | E.coli |
| Species | Human |
| Predicted Molecular Mass | 42.9 KDa |
| | |
| Formulation | Lyophilized from a 0.2 µm filtered solution of 20mM Tris-HCl, 150mM NaCl, 5% Trehalose, 5% Mannitol, 0.02% Tween 80, 1mM EDTA, pH8.0. |
| Formulation Shipping | Trehalose, 5% Mannitol, 0.02% Tween 80, 1mM EDTA, pH8.0. The product is shipped at ambient temperature. Upon receipt, store it |
| | Trehalose, 5% Mannitol, 0.02% Tween 80, 1mM EDTA, pH8.0. |

SDS-PAGE image



Background



Alternative Names Calreticulin-3; calreticulin-2; calsperin; CALR3; CRT2

Background Calreticulin-3 belongs to the calreticulin family, members of which are calcium binding chaperones localized mainly in the endoplasmic reticulum. It can be divided into a N-terminal globular domain, a proline-rich P-domain forming an elongated arm-like structure and a C-terminal acidic domain. During spermatogenesis process, Calreticulin-3 may act as a lectin-independent chaperone for specific client proteins such as ADAM3. Defects in CALR3 are the cause of familial hypertrophic cardiomyopathy type 19 (CMH19), it is a hereditary heart disorder characterized by ventricular hypertrophy, which is usually asymmetric and often involves the interventricular septum. The symptoms include dyspnea, syncope, collapse, palpitations, and chest pain.

Note

For Research Use Only, Not for Diagnostic Use.